Breaking News

Financial Report: AMRI

February 17, 2016

Contract revenue up 52% in the quarter

AMRI
 
4Q Revenues: $126.4 million (+46%)
 
4Q Earnings: $1.8 million (loss of $1.9 million 4Q14)
 
FY Revenues: $402.3 million (+45%)
 
FY Loss:
$2.3 million (loss of $3.3 million FY14)
 
Comments: Contract revenue for the quarter was $123.0 million, up 52%. Margins benefited from recent acquisitions, product mix within the Drug Product segment and the impact of cost reduction initiatives and facility optimization activities. Royalty revenue in the quarter was $3.4 million, down 43% due to lower royalties on Allegra products, which have ended based on the patent expirations.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision